{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:55:09Z","timestamp":1790272509995,"version":"4.1.0"},"reference-count":109,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Inhibitory immune pathways have gained considerable attention following the clinical success of immune checkpoint inhibitors in cancer. While much focus has been placed on classical checkpoints such as programmed cell death protein-1 (PD-1)\/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), alternative immunosuppressive mechanisms are increasingly recognized as contributors to immune evasion, tumor progression, and therapeutic resistance. Among these, non-classical human leukocyte antigens (HLAs), particularly HLA-G and its receptors ILT2 and ILT4, have emerged as key players regulating antitumor responses.<\/jats:p>\n                  <jats:p>This review highlights the HLA-G\/ILT2\/ILT4 axis as a distinct immunosuppressive pathway within the HLA family promoting immune escape. This pathway engages natural killer (NK) cells, myeloid cells, and antigen-experienced T cells through unique mechanisms and is characterized by effects on immune cell subsets and tumor expression profiles that are largely non-overlapping with PD-L1 and CTLA-4. These distinguishing features underscore its potential as a novel and promising pathway to expand the scope of immune checkpoint-based interventions.<\/jats:p>\n                  <jats:p>Although early-phase clinical studies have begun to explore this axis, robust evidence of therapeutic efficacy remains limited. Constraints such as small sample sizes, heavily pretreated patient populations, and an emphasis on PD-1 combinations in PD-1\/PD-L1 inhibitor-experienced patients may have hindered a clear assessment of its potential. Nonetheless, the unique biology of this pathway supports its potential as a novel target for cancer therapeutics. Continued research is needed to refine tumor subtypes, identify responsive patient subsets, and clarify their therapeutic relevance.<\/jats:p>","DOI":"10.1136\/jitc-2025-013313","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T19:25:16Z","timestamp":1771183516000},"page":"e013313","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Unlocking the promise of innate biology through the HLA-G\/ILT2\/ILT4 pathway"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4309-0988","authenticated-orcid":false,"given":"Courtney","family":"Beers","sequence":"first","affiliation":[{"name":"Tizona Therapeutics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Ilaria","sequence":"additional","affiliation":[{"name":"Tizona Therapeutics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J","family":"Luke","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"2026021511251019000_14.2.e013313.1","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/359748","article-title":"The dual role of HLA-G in cancer","volume":"2014","author":"Rouas-Freiss","year":"2014","journal-title":"J Immunol Res"},{"key":"2026021511251019000_14.2.e013313.2","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.105"},{"key":"2026021511251019000_14.2.e013313.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.11.005"},{"key":"2026021511251019000_14.2.e013313.4","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090978","article-title":"The Cynomolgus Macaque MHC Polymorphism in Experimental Medicine","volume":"8","author":"Shiina","year":"2019","journal-title":"Cells"},{"key":"2026021511251019000_14.2.e013313.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.16.9104"},{"key":"2026021511251019000_14.2.e013313.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409676102"},{"key":"2026021511251019000_14.2.e013313.7","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081213","article-title":"The Molecular Mechanisms of HLA-G Regulatory Function on Immune Cells during Early Pregnancy","volume":"13","author":"Mao","year":"2023","journal-title":"Biomolecules"},{"key":"2026021511251019000_14.2.e013313.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744324","article-title":"HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance","volume":"12","author":"Zhuang","year":"2021","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2000484117"},{"key":"2026021511251019000_14.2.e013313.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1431057100"},{"key":"2026021511251019000_14.2.e013313.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2022.103764"},{"key":"2026021511251019000_14.2.e013313.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.2.289"},{"key":"2026021511251019000_14.2.e013313.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2003.08.346"},{"key":"2026021511251019000_14.2.e013313.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.3.1376"},{"key":"2026021511251019000_14.2.e013313.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057125"},{"key":"2026021511251019000_14.2.e013313.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716289","article-title":"The Genomic Organization of the LILR Region Remained Largely Conserved Throughout Primate Evolution: Implications for Health And Disease","volume":"12","author":"Storm","year":"2021","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.11.1809"},{"key":"2026021511251019000_14.2.e013313.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801472"},{"key":"2026021511251019000_14.2.e013313.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0764"},{"key":"2026021511251019000_14.2.e013313.20","first-page":"219","article-title":"Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G","volume":"18","author":"Shiroishi","year":"2006","journal-title":"Int Immunol"},{"key":"2026021511251019000_14.2.e013313.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.10.5261"},{"key":"2026021511251019000_14.2.e013313.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2014.03.012"},{"key":"2026021511251019000_14.2.e013313.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03128-9"},{"key":"2026021511251019000_14.2.e013313.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282874","article-title":"Human leukocyte immunoglobulin-like receptors in health and disease","volume":"14","author":"Redondo-Garc\u00eda","year":"2023","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-135194"},{"key":"2026021511251019000_14.2.e013313.26","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1121324"},{"key":"2026021511251019000_14.2.e013313.27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004859","article-title":"BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression","volume":"10","author":"Mandel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026021511251019000_14.2.e013313.28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97570"},{"key":"2026021511251019000_14.2.e013313.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089771"},{"key":"2026021511251019000_14.2.e013313.31","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2015.04.001"},{"key":"2026021511251019000_14.2.e013313.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2368"},{"key":"2026021511251019000_14.2.e013313.33","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12119"},{"key":"2026021511251019000_14.2.e013313.34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.1.207"},{"key":"2026021511251019000_14.2.e013313.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.12.6100"},{"key":"2026021511251019000_14.2.e013313.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000547"},{"key":"2026021511251019000_14.2.e013313.37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.humimm.2016.02.012","article-title":"Mouse models for studies of HLA-G functions in basic science and pre-clinical research","volume":"77","author":"Nguyen-Lefebvre","year":"2016","journal-title":"Hum Immunol"},{"key":"2026021511251019000_14.2.e013313.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803341105"},{"key":"2026021511251019000_14.2.e013313.39","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1342023","article-title":"Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G\/ILT2\/ILT4","volume":"6","author":"Rouas-Freiss","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026021511251019000_14.2.e013313.40","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.3390\/ijms21124528","article-title":"HLA-G: A New Immune Checkpoint in Cancer?","volume":"21","author":"Krijgsman","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026021511251019000_14.2.e013313.41","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3389\/fimmu.2018.02164","article-title":"Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.42","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800751"},{"key":"2026021511251019000_14.2.e013313.43","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11456"},{"key":"2026021511251019000_14.2.e013313.44","first-page":"28","article-title":"Prognostic Value of HLA-G in Malignant Liver and Pancreas Lesions","volume":"15","author":"Khodabandeh Shahraki","year":"2018","journal-title":"Iran J Immunol"},{"key":"2026021511251019000_14.2.e013313.45","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1582-4934.2009.00917.x","article-title":"Aberrant human leucocyte antigen\u2010G expression and its clinical relevance in hepatocellular carcinoma","volume":"14","author":"Lin","year":"2010","journal-title":"J Cellular Molecular Medi"},{"key":"2026021511251019000_14.2.e013313.46","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/250435","article-title":"Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer","volume":"2013","author":"da Silva","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"2026021511251019000_14.2.e013313.47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4588"},{"key":"2026021511251019000_14.2.e013313.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029922","article-title":"Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins","volume":"7","author":"Morandi","year":"2012","journal-title":"PLoS One"},{"key":"2026021511251019000_14.2.e013313.49","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00083"},{"key":"2026021511251019000_14.2.e013313.50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.698677","article-title":"HLA-G\/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00011"},{"key":"2026021511251019000_14.2.e013313.52","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1582-4934.2009.00917.x","article-title":"Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma","volume":"14","author":"Lin","year":"2010","journal-title":"J Cell Mol Med"},{"key":"2026021511251019000_14.2.e013313.53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679090","article-title":"Prognostic Significance of Immune Checkpoints HLA-G\/ILT-2\/4 and PD-L1 in Colorectal Cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.54","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.111876","article-title":"JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G","volume":"28","author":"Obermajer","year":"2025","journal-title":"iScience"},{"key":"2026021511251019000_14.2.e013313.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2003.10.005"},{"key":"2026021511251019000_14.2.e013313.56","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.3390\/ijms21228678","article-title":"The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?","volume":"21","author":"Attia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026021511251019000_14.2.e013313.57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158265","article-title":"A Critical Assessment of the Association between HLA-G Expression by Carcinomas and Clinical Outcome","volume":"22","author":"van de Water","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026021511251019000_14.2.e013313.58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12885-023-10906-2","article-title":"Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma","volume":"23","author":"Zou","year":"2023","journal-title":"BMC Cancer"},{"key":"2026021511251019000_14.2.e013313.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.05.011"},{"key":"2026021511251019000_14.2.e013313.60","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3892\/mmr.2012.744","article-title":"Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance","volume":"5","author":"Zhang","year":"2012","journal-title":"Mol Med Rep"},{"key":"2026021511251019000_14.2.e013313.61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389411","article-title":"Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma","volume":"15","author":"Sakata","year":"2024","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.62","doi-asserted-by":"publisher","DOI":"10.1002\/path.1039"},{"key":"2026021511251019000_14.2.e013313.63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1851950","article-title":"Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression","volume":"9","author":"Vittrant","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026021511251019000_14.2.e013313.64","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151553","article-title":"Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy","volume":"7","author":"De Louche","year":"2022","journal-title":"JCI Insight"},{"key":"2026021511251019000_14.2.e013313.65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1049\/syb2.12058","article-title":"Comprehensive analysis of LILR family genes expression and tumour-infiltrating immune cells in early-stage pancreatic ductal adenocarcinoma","volume":"17","author":"Gao","year":"2023","journal-title":"IET Syst Biol"},{"key":"2026021511251019000_14.2.e013313.66","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1100"},{"key":"2026021511251019000_14.2.e013313.67","first-page":"1943","article-title":"Immunoglobulin\u2011like transcript 4 and human leukocyte antigen\u2011G interaction promotes the progression of human colorectal cancer","volume":"54","author":"Cai","year":"2019","journal-title":"Int J Oncol"},{"key":"2026021511251019000_14.2.e013313.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.044"},{"key":"2026021511251019000_14.2.e013313.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0096-5"},{"key":"2026021511251019000_14.2.e013313.70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06052-0","article-title":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","volume":"9","author":"Karaayvaz","year":"2018","journal-title":"Nat Commun"},{"key":"2026021511251019000_14.2.e013313.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0355-0"},{"key":"2026021511251019000_14.2.e013313.72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1535-7163.MCT-22-0351","article-title":"Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors","volume":"22","author":"Umiker","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026021511251019000_14.2.e013313.73","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28845"},{"key":"2026021511251019000_14.2.e013313.74","first-page":"6500","article-title":"Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells","volume":"118","author":"Agaugu\u00e9","year":"2011","journal-title":"Blood"},{"key":"2026021511251019000_14.2.e013313.75","doi-asserted-by":"crossref","first-page":"37385","DOI":"10.18632\/oncotarget.6044","article-title":"Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"2026021511251019000_14.2.e013313.76","doi-asserted-by":"crossref","first-page":"22158","DOI":"10.1038\/s41598-021-01572-0","article-title":"HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy","volume":"11","author":"Palma","year":"2021","journal-title":"Sci Rep"},{"key":"2026021511251019000_14.2.e013313.77","doi-asserted-by":"crossref","unstructured":"Lin Y , Chen M , Huang S , et al . Targeting Dual Immune Checkpoints PD\u2010L1 and HLA\u2010G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer. Adv Sci (Weinh) 2024;11. doi:10.1002\/advs.202309697","DOI":"10.1002\/advs.202309697"},{"key":"2026021511251019000_14.2.e013313.78","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3389\/fimmu.2020.02046","article-title":"Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary","volume":"11","author":"Schwich","year":"2020","journal-title":"Front Immunol"},{"key":"2026021511251019000_14.2.e013313.79","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3390\/ijms23062925","article-title":"HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies","volume":"23","author":"Morandi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021511251019000_14.2.e013313.80","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2026021511251019000_14.2.e013313.81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45816"},{"key":"2026021511251019000_14.2.e013313.82","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445353"},{"key":"2026021511251019000_14.2.e013313.83","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl9171","article-title":"Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy","volume":"8","author":"Cao","year":"2022","journal-title":"Sci Adv"},{"key":"2026021511251019000_14.2.e013313.84","unstructured":"Sanofi . Study of sar444881 administered alone and in combination with other therapeutics in participants with advanced solid tumors. clinicaltrials.gov identifier: nct04717375 . ClinicalTrials.gov; 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT04717375"},{"key":"2026021511251019000_14.2.e013313.85","article-title":"990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors","volume":"35","author":"Perets","year":"2024","journal-title":"Invest Immunother"},{"key":"2026021511251019000_14.2.e013313.86","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0568"},{"key":"2026021511251019000_14.2.e013313.87","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1200\/JCO.2024.42.16_suppl.2582","article-title":"Phase 1\/2 study of NGM707, an ILT2\/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Onco"},{"key":"2026021511251019000_14.2.e013313.88","first-page":"494","article-title":"OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses","volume":"11","author":"Bouchlaka","year":"2023","journal-title":"J Immunother Cance"},{"key":"2026021511251019000_14.2.e013313.89","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010006","article-title":"Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors","volume":"12","author":"Taylor","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026021511251019000_14.2.e013313.90","unstructured":"OncoResponse, Inc . A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents. ClinicalTrials.gov Identifier: NCT06090266 . ClinicalTrials.gov; 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT06090266"},{"key":"2026021511251019000_14.2.e013313.91","first-page":"A1684","article-title":"Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in patients with advanced cancers","volume":"12","author":"Sen","year":"2024","journal-title":"J Immunother Cance"},{"key":"2026021511251019000_14.2.e013313.92","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.2025.43.16_suppl.2524","article-title":"Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), \u00b1 cemiplimab in patients with advanced solid tumors from a phase 1 study","volume":"43","author":"Sen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026021511251019000_14.2.e013313.93","unstructured":"Jounce Therapeutics, Inc . Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors. ClinicalTrials.Gov Identifier: NCT04669899 . ClinicalTrials.gov; 2024. Available: https:\/\/clinicaltrials.gov\/study\/NCT04669899"},{"key":"2026021511251019000_14.2.e013313.94","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2024.42.16_suppl.4531","article-title":"Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial","volume":"42","author":"Primo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021511251019000_14.2.e013313.95","unstructured":"Immune-Onc Therapeutics . First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors. ClinicalTrials.gov Identifier: NCT05054348 . ClinicalTrials.gov; 2024. Available: https:\/\/clinicaltrials.gov\/study\/NCT05054348"},{"key":"2026021511251019000_14.2.e013313.96","first-page":"532","article-title":"Preclinical characterization of a first-in-class ILT4 antagonist, MK-4830","volume":"6","author":"Zuniga","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026021511251019000_14.2.e013313.97","unstructured":"Merck Sharp & Dohme LLC . Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001). ClinicalTrials.gov Identifier: NCT03564691 . ClinicalTrials.gov; 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT03564691"},{"key":"2026021511251019000_14.2.e013313.98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2160"},{"key":"2026021511251019000_14.2.e013313.99","article-title":"Targeting HLA-G\u2013mediated immunosuppression with a first-in-class antagonist antibody (TTX-080)","volume":"8","author":"Hodges","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"2026021511251019000_14.2.e013313.100","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.2024.42.16_suppl.2524","article-title":"Results from phase 1a\/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma","volume":"42","author":"Ulahannan","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021511251019000_14.2.e013313.101","doi-asserted-by":"crossref","first-page":"114052","DOI":"10.1016\/j.intimp.2025.114052","article-title":"Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications","volume":"147","author":"Piao","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2026021511251019000_14.2.e013313.102","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1538-7445.AM2024-3641","article-title":"Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2\/ILT4 dual antagonist antibody, in patients with advanced solid tumors","volume":"84","author":"Blum","year":"2024","journal-title":"Cancer Res"},{"key":"2026021511251019000_14.2.e013313.103","article-title":"570 TTX-080, a first-in-class HLA-G specific antagonist, increases distinct innate and adaptive immune cells in the tumor microenvironment and periphery","volume":"13","author":"Beers","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"2026021511251019000_14.2.e013313.104","unstructured":"Biond Biologics . A study of BND-35 in participants with advanced solid tumors. ClinicalTrials.gov Identifier: NCT06274437 . ClinicalTrials.gov; 2024. Available: https:\/\/clinicaltrials.gov\/study\/NCT06274437"},{"key":"2026021511251019000_14.2.e013313.105","unstructured":"Duey DM , Ebens AJ , Kaplan DD , et al . ILT-binding agents and methods of use thereof. WO 2021222544A1. PCT application PCT\/US2021\/029866. 2021."},{"key":"2026021511251019000_14.2.e013313.106","doi-asserted-by":"crossref","first-page":"100284","DOI":"10.1016\/j.iotech.2022.100284","article-title":"172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors","volume":"16","author":"Papadopoulos","year":"2022","journal-title":"Immuno-Oncology and Technology"},{"key":"2026021511251019000_14.2.e013313.107","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0041"},{"key":"2026021511251019000_14.2.e013313.108","unstructured":"Hoffmann-La Roche . A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (MORPHEUS-LIVER). ClinicalTrials.gov Identifier: NCT04524871 . 2026. Available: https:\/\/clinicaltrials.gov\/study\/NCT04524871"},{"key":"2026021511251019000_14.2.e013313.109","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1158\/1538-7445.AM2022-2906","article-title":"Abstract 2906: AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses","volume":"82","author":"Udartseva","year":"2022","journal-title":"Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T19:25:25Z","timestamp":1771183525000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":109,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,15]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013313"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013313","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}